Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China,
Hepatol Int. 2007 Jun;1(2):316-25. doi: 10.1007/s12072-007-9006-5. Epub 2007 Jun 6.
Chronic hepatitis B virus infection, a major cause of end-stage liver disease and hepatocellular carcinoma, is a worldwide health concern. While the past two decades have brought major advances in the availability of treatments to help delay or prevent these outcomes, treatment of chronic hepatitis B remains a serious challenge, not least due to the ability of the virus to remain in hepatocyte nuclei as a source of potential reactivation-hence the term chronic hepatitis B infection. This article reviews the current treatments available and suggests a framework for a rational approach to managing the disease.
慢性乙型肝炎病毒感染是终末期肝病和肝细胞癌的主要病因，也是全球关注的健康问题。尽管过去二十年在提供治疗方法以帮助延缓或预防这些结局方面取得了重大进展，但慢性乙型肝炎的治疗仍然是一个严峻的挑战，尤其是因为病毒能够以潜在再激活的来源存在于肝细胞核内——这就是慢性乙型肝炎感染这一术语的由来。本文综述了现有的治疗方法，并提出了一种合理管理该病的方法框架。
